{"prompt": "['OSTPDL1', 'Page 37 of 60', 'Formulation and stability: The product is a sterile, clear and colorless', 'solution presented at concentration of 20mg/mL in United States', 'Pharmacopeia (USP) type I glass vials closed with a rubber stopper and', 'sealed with an aluminum Flip Off\u00a9 crimp seal closure. Each single use', '20mg/mL vial contains 200mg of avelumab as a preservative-free', 'acetate-buffered solution (ph 5.2) containing mannitol and polysorbate', '20 (Tween 20). Only excipients that conform to the current USP are used.', 'Storage: Avelumab vials must be stored at 2\u00b0C to 8\u00b0C until use. Vials that', 'are stored at room or higher temperature for extended periods of time', 'may be subject to degradation. The drug product must not be frozen.', 'Rough shaking of solution must be avoided.', 'Solution preparation: Avelumab must be diluted with 0.9% saline solution', '(sodium chloride injection) supplied in an infusion bag to a total volume', 'of 250mL. Prior to preparation of dilution, each vial should be allowed to', 'equilibrate to room temperature. For mixing purposes, after dilution of', 'avelumab in the infusion bag, the mixture should be gently inverted 10', 'times. Vial contents from different lots should not be mixed in the same', 'infusion.', 'Stability. The chemical and physical n-use stability for the infusion', 'solution of avelumab in 0.9% saline solution (sodium chloride injection)', 'has been demonstrated for a total of 24 hours at room temperature.', 'However, from a microbiological point of view, this solution should be', 'used immediately and is not intended to be stored unless dilution has', 'taken place in a controlled and validation aseptic condition', 'Supplier: Pfizer will supply avelumab to all participating institutions.', 'Toxicity: Most commonly reported adverse events are fatigue, influenza-', \"like illness, pyrexia, lymphopenia. See Investigator's Brochure for full\", 'description.', 'Dosage and route of administration: Avelumab should be administered as', 'an intravenous infusion over 60 minutes. Premedication is required; see', 'treatment plan sections.', '7.0', 'REQUIRED EVALUATIONS, TESTS, AND OBSERVATIONS', '7.1', 'Evaluations Before and During Therapy', \"All participants enrolled at St. Jude Children's Research Hospital should\", 'be invited to participate in the St. Jude tissue banking protocol (TBANK)', 'and pharmacogenetics protocol PGEN5 at the time of study entry. All', 'clinical and laboratory studies to determine eligibility must be performed', 'within 7 days prior to enrollment unless otherwise indicated. Imaging', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201) APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 38 of 60', 'studies must be obtained within 14 days prior to the start of protocol', 'therapy (repeat tumor imaging if necessary).', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}